In a major leap forward for urological oncology, scientists have successfully validated a revolutionary non-invasive urine test capable of identifying bladder cancer with unprecedented precision [1.21]. The genomic assay, known as GALEAS Bladder, isolates and analyzes trace DNA shed into fluid samples to detect malignant cells, registering a 92.2% overall accuracy rate. Crucially, the diagnostic tool achieved a flawless 100% detection rate for highly aggressive, muscle-invasive tumors, offering a painless, screening alternative that can confidently replace uncomfortable hospital cystoscopies.
About the Author
